Advice

following a full submission:

pembrolizumab (Keytruda®) is accepted for use within NHSScotland.

Indication under review: in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.

In a double-blind, phase III study, addition of pembrolizumab to carboplatin plus paclitaxel chemotherapy significantly improved progression-free survival in adults undergoing first-line treatment of primary advanced or recurrent endometrial carcinoma.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2767
Indication:

In combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.

Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
07 July 2025